Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia

Neurosci Lett. 1998 May 22;248(1):5-8. doi: 10.1016/s0304-3940(98)00303-6.

Abstract

Reduction of non-protein-bound iron (NPBI) using iron chelators may attenuate hypoxia-ischemia-induced reperfusion injury of the brain. This study investigated whether administration of low-dose deferoxamine and allopurinol, both having NPBI-chelating properties, reduced hypoxia-ischemia-induced NPBI formation in plasma effluent from the brain and in cerebral cortical tissue. Twenty-one newborn lambs underwent severe hypoxia-ischemia. Upon reperfusion and reoxygenation the lambs received either a placebo (n = 7), or deferoxamine 2.5 mg/kg (n = 7) or allopurinol 20 mg/kg (n = 7). The post-hypoxic-ischemic NPBI levels in plasma were significantly lower after deferoxamine but not after allopurinol as compared to placebo-treated lambs. Cortical NPBI levels in both deferoxamine and allopurinol-treated lambs were significantly lower than NPBI levels in placebo-treated lambs. We conclude that deferoxamine effectively lowers NPBI in plasma effluent from the brain, and that both, deferoxamine and allopurinol, lower NPBI in cortical brain tissue.

MeSH terms

  • Allopurinol / pharmacology*
  • Animals
  • Animals, Newborn
  • Brain Ischemia / metabolism*
  • Cerebral Cortex / drug effects
  • Cerebral Cortex / metabolism
  • Deferoxamine / pharmacology*
  • Hypoxia, Brain / metabolism*
  • Iron / blood*
  • Iron Chelating Agents / pharmacology*
  • Nerve Tissue Proteins / metabolism
  • Protein Binding / drug effects
  • Sheep

Substances

  • Iron Chelating Agents
  • Nerve Tissue Proteins
  • Allopurinol
  • Iron
  • Deferoxamine